Novo Nordisk's CagriSema Delivers in Two Phase 3 Trials as EU Panel Backs Hemophilia and Growth Therapies

CagriSema hit 21% weight loss in REDEFINE 9 and two CHMP positive opinions landed, but Novo Nordisk shares remain under pressure.

Fresh clinical readouts and a pair of European regulatory endorsements have handed Novo Nordisk a trio of pipeline wins, even as the Danish drugmaker's shares continue to struggle under the weight of investor doubts about its longer-term growth story.

CagriSema clears the bar in obesity and diabetes studies

In the Phase 3 REDEFINE 9 trial, the dual-action candidate CagriSema produced a 21% weight loss at week 68 in adults who were overweight or living with obesity, compared with placebo. The result reinforces the company's effort to hold its ground in the increasingly crowded weight-loss market, where management views the drug as a cornerstone of future expansion.

A second study, REIMAGINE 5, tested the therapy in adults with type 2 diabetes. At week 60, the 1.0 mg/1.0 mg dose of CagriSema achieved a 12.4% reduction in body weight, against 9.1% for tirzepatide at the 5 mg dose. The trial also confirmed that CagriSema was non-inferior on HbA1c lowering. Together, the data give the company solid clinical ammunition in the battle for share in the lucrative diabetes and obesity segment, and suggest the combination therapy could entrench Novo Nordisk's leadership if the efficacy holds up in upcoming approval proceedings.

Two European nods open the door to new markets

Regulatory progress in Europe arrived in quick succession. On Friday, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval for Sogroya, a once-weekly somapacitan for children with idiopathic short stature and ongoing growth disturbances. A day earlier, the same panel issued a positive opinion for FREHEMGO (denecimig) in hemophilia A.

FREHEMGO is the first FVIIIa mimetic to allow prophylaxis at weekly, biweekly or monthly intervals via a single-use prefilled pen — a practical advantage for patients managing the bleeding disorder. Novo Nordisk intends to launch the product in the first European countries in the fourth quarter of 2026, with a broader EU rollout to follow from early 2027.

The company is also pressing ahead with capital allocation, with transactions to date totaling roughly DKK 9.63 billion.

Strategy day leaves the market cold

Those pipeline and regulatory gains stand in sharp contrast to the mood among investors. At a capital markets day, CEO Mike Doustdar pledged to bring several blockbusters to market before the end of the decade and to deliver revenue growth on par with leading pharmaceutical firms. He also outlined plans to broaden the pipeline and market future products more like consumer goods, targeting at least five so-called multi-blockbuster launches by 2030 and more than $23 billion in new revenue over the coming years.

What many shareholders wanted — concrete near-term plans for an operational turnaround — did not materialize. The disappointment triggered pronounced selling pressure. According to Bloomberg, the stock fell as much as 7.7% in early trading yesterday. By Tuesday, the shares were changing hands at EUR 34.62, a modest daily decline of 0.6%. At a recent price of EUR 34.51, the loss since the start of the year stands at 22%.

Analysts have been adjusting their views accordingly. Deutsche Bank cut its price target on the Danish stock from DKK 265 to DKK 245, while Jefferies rated the shares "Hold" the same day.

Execution is now the test

The central question for market participants is whether Novo Nordisk can translate its clinical momentum into meaningful market share beyond its established diabetes and obesity strongholds. FREHEMGO's flexible dosing schedule should support rapid uptake once it reaches the market, and a successful launch would widen the company's revenue base. Conversely, a slower-than-expected rollout from early 2027 would put Doustdar's growth assumptions under strain, all the more so given the intense competition in the newly targeted indications. Higher distribution costs and lower-margin revenue streams are among the risks investors fear as the group transforms into a broader healthcare player.

Attention now turns to the next formal approval steps. The European Commission's final decision on FREHEMGO is expected within a few months of the positive CHMP opinion, followed by the first country launches in the fourth quarter of 2026 — the earliest reliable gauge of real demand in the hemophilia A market. As long as the stock can defend its 52-week low of EUR 30.25, there is room for stabilization on the back of the new product approvals. Should that support give way amid persistent doubts about the 2030 earnings targets, a further re-rating of the growth outlook looms.